Andjelka Stones/Pinterest
Jun 5, 2026, 15:53
Andjelka Stones: Key Findings on Hemophilia A Gene Therapy
Andjelka Stones, Former Distinguished Adjunct Professor at NorthCentral University, shared a post on LinkedIn:
“Hemophilia A Gene Therapy
Gene therapy for hemophilia A: 4‑year data from the Phase 3 GENEr8‑1 trial are out.
Key findings (n=134):
- Mean treated bleed rate 82.6% from baseline
- Factor VIII infusion rate 95.5%
- 73.6% of patients had zero treated bleeds in year 4
- Mean FVIII activity at year 4: 16.1 IU/dL
- Only 18% of patients resumed prophylaxis
No new safety signals were observed. Health‑related quality of life remained improved.
This is the longest and largest Phase 3 follow‑up of a gene therapy in hemophilia.
Durable benefit after a single infusion.
Full citation in my archive.”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI